Last $64.93 USD
Change Today -0.61 / -0.93%
Volume 368.3K
Q On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Snapshot

Open
$65.39
Previous Close
$65.54
Day High
$65.40
Day Low
$64.60
52 Week High
02/23/15 - $66.28
52 Week Low
04/30/14 - $46.27
Market Cap
8.1B
Average Volume 10 Days
464.4K
EPS TTM
$2.70
Shares Outstanding
124.3M
EX-Date
--
P/E TM
24.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (Q)

quintiles transnational hold (Q) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (Q) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, and market access and commercialization consulting services; real-world late phase services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, including digital patient, and brand and scientific communications services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

32,600 Employees
Last Reported Date: 02/12/15
Founded in 1982

quintiles transnational hold (Q) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $871.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.1M
Compensation as of Fiscal Year 2013.

quintiles transnational hold (Q) Key Developments

Quintiles Appoints Elgar Peerschke as President of Advisory Services

Quintiles announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles Advisory Services organization and the continued development and delivery of its related services. Elgar joins Quintiles from Bain & Company, where he was a senior partner in its Global Healthcare Practice Group and a leading client service partner. Prior to Bain, Elgar spent more than a decade at McKinsey and Company in various leadership roles.

Quintiles Transnational Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Quintiles Transnational Holdings Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $1,411,088,000 against $1,379,185,000 a year ago. Income from operations was $158,932,000 against $127,012,000 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $132,868,000 against $100,042,000 a year ago. Net income was $88,444,000 against $72,934,000 a year ago. Net income attributable to company was $88,426,000 against $72,996,000 a year ago. Earnings per share diluted attributable to common shareholder was $0.69 against $0.55 per share a year ago. Adjusted EBITDA was $196,071,000 against $159,740,000 a year ago. Adjusted income from operations was $164,171,000 against $129,186,000 a year ago. Adjusted net income was $91,849,000 against $73,002,000 a year ago. Diluted adjusted earnings per share were $0.71 against $0.55 per share a year ago. For the year, the company reported total revenues of $5,459,998,000 against $5,099,545,000 a year ago. Income from operations was $590,390,000 against $462,333,000 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $502,189,000 against $323,116,000 a year ago. Net income was $356,501,000 against $226,027,000 a year ago. Net income attributable to company was $356,383,000 against $226,591,000 a year ago. Earnings per share diluted attributable to common shareholder was $2.72 against $1.77 per share a year ago. Net cash provided by operating activities was $431,754,000 against $393,371,000 a year ago. Acquisition of property, equipment and software was $82,650,000 against $88,347,000 a year ago. Adjusted EBITDA was $720,391,000 against $611,602,000 a year ago. Adjusted income from operations was $599,378,000 against $504,098,000 a year ago. Adjusted net income was $353,418,000 against $264,030,000 a year ago. Diluted adjusted earnings per share were $2.70 against $2.06 per share a year ago. For the year 2015, the company expects net income of range between $371 million to $389 million. Earnings per share of range between $2.90 to $3.04 per share. Tax effect of adjustments range between $8 million to $6 million. Adjusted net income and diluted adjusted earnings per share range between $386 million or $3.02 per share between $401 million or $3.13 per share. Annual effective income tax rate estimated at approximately 29.5%.

Quintiles Announces Board Changes

Quintiles Transnational Holdings Inc. announced the transition of Dennis Gillings from his role as executive chairman and chairman of the board at the end of 2015 and that he will remain on the board as a director. Quintiles' Stockholders Agreement has been amended, calling for the Quintiles Board to be set at nine members, comprised of a majority of independent directors by November 2015. In the interim, the Board size will be increased to 13 to make room for two additional independent directors, the first of whom is Dr. John Leonard, an experienced pharmaceutical development executive, who was appointed to the Board on February 5, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $64.93 USD -0.61

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $76.61 USD +0.99
ICON PLC $67.72 USD -0.34
IMS Health Holdings Inc $26.68 USD +0.12
INC Research Holdings Inc $29.49 USD -0.16
PAREXEL International Corp $64.29 USD -0.76
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 24.1x
Price/Sales 2.0x
Price/Book NM Not Meaningful
Price/Cash Flow 22.9x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.